In a filing, LifeMD Inc revealed its Officer FRIEDEMAN JESSICA acquired Company’s shares for reported $80800.0 on Nov 24 ’25. In the deal valued at $4.04 per share,20,000 shares were bought.
Then, Alvarez Nicholas P sold 75,000 shares, generating $443,760 in total proceeds. Upon selling the shares at $5.92, the Chief Acquisition Officer now owns 605,000 shares.
Before that, Alvarez Nicholas P bought 75,000 shares. LifeMD Inc shares valued at $459,000 were divested by the Officer at a price of $6.12 per share.
BTIG Research reiterated its LifeMD Inc [LFMD] rating to a Buy in a research note published on June 18, 2025; the price target was $18. A number of analysts have revised their coverage, including Lake Street’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Mizuho began covering LFMD with “Neutral” recommendation on December 04, 2024.
Price Performance Review of LFMD
On Tuesday, LifeMD Inc [NASDAQ:LFMD] saw its stock fall -0.28% to $3.56. Over the last five days, the stock has lost -10.33%. LifeMD Inc shares have fallen nearly -44.03% since the year began. Nevertheless, the stocks have fallen -28.08% over the past one year. While a 52-week high of $15.84 was reached on 06/23/25, a 52-week low of $3.43 was recorded on 11/18/25.
Levels Of Support And Resistance For LFMD Stock
The 24-hour chart illustrates a support level at 3.47, which if violated will result in even more drops to 3.39. On the upside, there is a resistance level at 3.63. A further resistance level may holdings at 3.71.
How much short interest is there in LifeMD Inc?
A steep rise in short interest was recorded in LifeMD Inc stocks on 2025-11-14, growing by 0.22 million shares to a total of 4.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 4.17 million shares. There was a rise of 4.91%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 05, 2024 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $12 price target.
